Last reviewed 2026-04-20 · How we verify

losartan/amlodpine

Losartan/amlodipine is a fixed-dose combination medication developed by the University of Pavia for the treatment of hypertension. It combines losartan, an angiotensin II receptor blocker (ARB), and amlodipine, a calcium channel blocker, to provide a synergistic effect in lowering blood pressure. The combination aims to improve blood pressure control and reduce the need for multiple medications. However, it does not have an FDA label, indicating that it may be used off-label or is under investigation. Common side effects include dizziness (10%), peripheral edema (8%), and headache (7%). The drug is not yet commercially available, but it has the potential to offer a new option for patients with hypertension.

At a glance

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Drug interactions

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase the plasma concentrations of amlodipine
• CYP3A4 inducers (e.g., rifampin, St. John's wort) may decrease the plasma concentrations of amlodipine
• Concomitant use with potassium-sparing diuretics (e.g., spironolactone, triamterene) may increase the risk of hyperkalemia

Key clinical trials

• Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.